ClinicalTrials.Veeva

Menu

-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.

G

Glostrup University Hospital, Copenhagen

Status

Completed

Conditions

Type 2 Diabetes

Treatments

Dietary Supplement: GPR 119 agonist, 2-oleyl glycerol
Dietary Supplement: Vehicle
Dietary Supplement: Oleic acid

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to evaluate the impact of different ligands of GPR 119 (a G protein-coupled receptor in the intestine) on the secretion of the incretin hormones, GLP-1 and GIP.

Full description

We have found a new ligand for the GPR 119 receptor. This study evaluate the impact of this ligand on the incretion hormone responses, beta cell function and gall bladder function in healthy young men.

Enrollment

8 patients

Sex

Male

Ages

18 to 30 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy caucasians v- Normal OGTT (75 g of glucose) according to WHO's criteria
  • Normal hemoglobin
  • Informed consent

Exclusion criteria

  • Liver disease (ALAT> 2x normal level)
  • Nephropathy (s-creatinin >130 microM or albuminuria)
  • Relatives with type 2 diabetes

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

8 participants in 3 patient groups, including a placebo group

GPR119 agonist, 2-oleoyl glycerol
Experimental group
Description:
2-oleoyl glycerol; 2g. and vehicle
Treatment:
Dietary Supplement: GPR 119 agonist, 2-oleyl glycerol
Dietary Supplement: Vehicle
Oleic acid
Active Comparator group
Description:
oleic acid; 3.2g and vehicle
Treatment:
Dietary Supplement: Vehicle
Dietary Supplement: Oleic acid
Vehicle
Placebo Comparator group
Description:
5 ml. of glycerol and 5 ml 96% ethanol
Treatment:
Dietary Supplement: Vehicle

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems